Loading
Telik
Telik was a Palo Alto biotech whose glutathione analogue canfosfamide (Telcyta) failed its phase 3 trials in ovarian and lung cancer in the 2000s, a reminder that late-stage failure is the norm in oncology.
Also called: Telik, Inc.
Overview
Telik, Inc., founded in 1988 in Palo Alto, California, developed canfosfamide (TLK286, Telcyta), a prodrug activated by glutathione S-transferase P1-1 that is overexpressed in many tumours. It led phase 3 trials in platinum-resistant ovarian cancer and non-small cell lung cancer, none of which met their primary endpoints, and the company later wound down its programmes. Its trials remain on ClinicalTrials.gov under Telik as lead sponsor.
Connected
5Similar pages
- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyVion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Cytotoxic chemotherapy.
- CompanyPregLem
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyPeregrine Pharmaceuticals (now Avid Bioservices)
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
telik.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Link orphan sponsor companies, repoint AAA trials to Nova… · diff · file
Sourced, not expert-reviewed